Literature DB >> 9248777

Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal.

M Cohen1, J Panagides, C J Timmer, J A Huisman.   

Abstract

The effect of a high-fat meal on the pharmacokinetics of mirtazapine was studied in 19 healthy normal young male volunteers. In a randomized two-period crossover study, each volunteer received an oral dose of 15 mg of mirtazapine in the form of tablets, in the fasting state and after a high-fat meal, with a washout period of 14 days between the two doses. Serial blood samples were taken and pharmacokinetic parameters calculated and statistically analyzed from mirtazapine plasma levels. The extent of absorption of mirtazapine, as measured by the area under the plasma level versus time curve, was found to be equivalent for the fasting and the fed state. Food intake was shown to have no influence on the elimination of mirtazapine, as measured by its elimination half-life. The rate of mirtazapine absorption, as measured by the peak level (Cmax), was not altered by food. The peak time (tmax), however, in subjects in the fed state showed an increase: the 90%-confidence interval for the median difference ranged from 0.25 to 1.25 h. This was the only effect of food found in this study. It is considered to be of no clinical consequence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9248777     DOI: 10.1007/BF03189792

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  11 in total

1.  A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression.

Authors:  J Mullin; A Lodge; E Bennie; R McCreadie; G S Bhatt; G Fenton
Journal:  J Psychopharmacol       Date:  1996-01       Impact factor: 4.153

2.  Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma.

Authors:  J E Paanakker; H J van Hal
Journal:  J Chromatogr       Date:  1987-06-05

3.  Bioequivalence revisited: non-parametric analysis of two-period cross-over studies.

Authors:  H P Wijnand
Journal:  Comput Methods Programs Biomed       Date:  1993-08       Impact factor: 5.428

4.  A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression.

Authors:  M Marttila; J Jääskeläinen; R Järvi; M Romanov; E Miettinen; P Sorri; U Ahlfors; M Zivkov
Journal:  Eur Neuropsychopharmacol       Date:  1995-12       Impact factor: 4.600

5.  A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.

Authors:  J D Bremner
Journal:  J Clin Psychiatry       Date:  1995-11       Impact factor: 4.384

6.  Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers.

Authors:  T H de Boer; G Maura; M Raiteri; C J de Vos; J Wieringa; R M Pinder
Journal:  Neuropharmacology       Date:  1988-04       Impact factor: 5.250

7.  The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo.

Authors:  T De Boer; F Nefkens; A Van Helvoirt
Journal:  Eur J Pharmacol       Date:  1994-02-21       Impact factor: 4.432

8.  A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients.

Authors:  O J Høyberg; B Maragakis; J Mullin; D Norum; E Stordall; P Ekdahl; E Ose; K M Moksnes; C Sennef
Journal:  Acta Psychiatr Scand       Date:  1996-03       Impact factor: 6.392

9.  A double-blind placebo-controlled study of Org 3770 in depressed outpatients.

Authors:  J L Claghorn; M D Lesem
Journal:  J Affect Disord       Date:  1995-06-08       Impact factor: 4.839

10.  Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression.

Authors:  M van Moffaert; J de Wilde; A Vereecken; M Dierick; J L Evrard; J Wilmotte; J Mendlewicz
Journal:  Int Clin Psychopharmacol       Date:  1995-03       Impact factor: 1.659

View more
  3 in total

Review 1.  Mirtazapine: a review of its use in major depression.

Authors:  K J Holm; A Markham
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of mirtazapine.

Authors:  C J Timmer; J M Sitsen; L P Delbressine
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

Review 3.  A risk-benefit assessment of mirtazapine in the treatment of depression.

Authors:  S Kasper; N Praschak-Rieder; J Tauscher; R Wolf
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.